SUBSEQUENT EVENTS DISCLOSURE	12 Months Ended
Aug. 31, 2024
Notes
SUBSEQUENT EVENTS DISCLOSURE	NOTE 15. SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company has analyzed its operations subsequent to August 31, 2024 to the date these financial statements were issued and has determined that it has the following material subsequent events to disclose in these financial statements, other than those disclosed above and below. On September 16, 2024, the Company issued 20,000,000 shares to the CEO as remuneration. Between September 25, 2024 and November 27, 2024, the Company issued 16,800,000 shares on conversion of a convertible loan note. On October 9, 2024, the Company announced the launch of InTheZone Labs, a new market vertical and subsidiary of the Company operating in partnership with a leading US-based bioceutical and nutraceutical manufacturing facility. This new expansion positions the Company at the forefront of the health and wellness market, specifically for enhanced mental focus, vitality and cognitive development. The first step is a Phase One Study to validate the InTheZone Labs product line and its effectiveness. On November 4, 2024, the Company issued 100,000,000 shares to the CEO as remuneration. On December 12, 2024, the Company announced the placement of its first InTheZone products on Amazon, allowing the product lines to start sales in early 2025, with further products being added as soon as possible. On March 3, 2025, the Company issued 200,000,000 shares to the CEO as remuneration. On March 18, 2025, following notice from the SEC, under SEC Rule 15c2-11, the Company’s stock was moved to ‘expert status’, meaning that, while it can still be traded, no unsolicited quotations may be received for the stock, severely limiting the marketability of the stock. On June 5, the SEC wrote again to the Company to insist that the Company file all delinquent reports as soon as possible, including this 10K and 10Qs relating to subsequent periods ending November 30, 2024 and February 28, 2025. At August 11, 2025, to avoid the stock being completely delisted, the Company must file up to date reports with the SEC as soon as possible. On August 5, 2025, the Company cancelled 1,999,967 shares originally issued in error to the CEO on June 20, 2024.

SUBSEQUENT EVENTS DISCLOSURE

12 Months Ended

Aug. 31, 2024

NOTE 15. SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to August 31, 2024 to the date these financial statements were issued and has determined that it has the following material subsequent events to disclose in these financial statements, other than those disclosed above and below.

On September 16, 2024, the Company issued 20,000,000 shares to the CEO as remuneration.

Between September 25, 2024 and November 27, 2024, the Company issued 16,800,000 shares on conversion of a convertible loan note.

On October 9, 2024, the Company announced the launch of InTheZone Labs, a new market vertical and subsidiary of the Company operating in partnership with a leading US-based bioceutical and nutraceutical manufacturing facility. This new expansion positions the Company at the forefront of the health and wellness market, specifically for enhanced mental focus, vitality and cognitive development. The first step is a Phase One Study to validate the InTheZone Labs product line and its effectiveness.

On November 4, 2024, the Company issued 100,000,000 shares to the CEO as remuneration.

On December 12, 2024, the Company announced the placement of its first InTheZone products on Amazon, allowing the product lines to start sales in early 2025, with further products being added as soon as possible.

On March 3, 2025, the Company issued 200,000,000 shares to the CEO as remuneration.

On March 18, 2025, following notice from the SEC, under SEC Rule 15c2-11, the Company’s stock was moved to ‘expert status’, meaning that, while it can still be traded, no unsolicited quotations may be received for the stock, severely limiting the marketability of the stock. On June 5, the SEC wrote again to the Company to insist that the Company file all delinquent reports as soon as possible, including this 10K and 10Qs relating to subsequent periods ending November 30, 2024 and February 28, 2025. At August 11, 2025, to avoid the stock being completely delisted, the Company must file up to date reports with the SEC as soon as possible.

On August 5, 2025, the Company cancelled 1,999,967 shares originally issued in error to the CEO on June 20, 2024.